Hikma invests in Chrono Therapeutics for the development of next generation transdermal drug delivery techbology
Chrono Therapeutics is developing a wearable transdermal drug delivery device offering a personalised behavioural support system that times nicotine delivery to when smokers have their strongest cravings.
Hikma Pharmaceuticals' (Hikma) venture capital arm, Hikma International Ventures and Development (Hikma Ventures) has participated in a $47.6 million series B round of financing for Chrono Therapeutics.
Chrono Therapeutics is developing a wearable transdermal drug delivery device offering a personalised behavioural support system that times nicotine delivery to when smokers have their strongest cravings. The Chrono solution is designed to deliver the first dose of nicotine replacement therapy shortly before a smoker wakes up, and then creates a pattern of “peaks and troughs” of nicotine delivery throughout the rest of the day to assure the smoker has more nicotine support when cravings are predicted to be strongest. The first application for this new technology is targeted for smoking cessation, but may also offer other advantages across other indications such as opioid addiction, Parkinson’s disease, and pain management.
The investment in Chrono Therapeutics demonstrates Hikma Ventures’ commitment to support the advancement of start-up companies with robust management teams and R&D expertise.
Lana Ghanem, Managing Director of Hikma Ventures, said: “We are very excited to announce our investment in Chrono Therapeutics, a pioneer in digital drug therapy for the treatment of smoking addiction. Targeting opportunities that enhance value creation for the business is key to Hikma Ventures’ approach. We believe that this investment – which is our first in a start-up company – has significant potential and is aligned with our strategy of investing in the exciting consumer and digital health segments.”
Alan Levy, CEO of Chrono Therapeutics said: We are very pleased to be working with Hikma Ventures given their focus on digital health and commitment to making innovative global solutions. Smoking is one of the leading causes of preventable death worldwide and Chrono’s platform has the potential to save lives well beyond the US. Hikma has a strong record of manufacturing and marketing pharmaceuticals globally, and will be important to us when the time comes to bring our smoking cessation technology to these markets.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance